Skip Nav Destination
Combinations of idelalisib with rituximab and/or bendamustine in patients with recurrent indolent non-Hodgkin lymphoma
Issue Archive
December 13 2016
Table of Contents
CLINICAL TRIALS AND OBSERVATIONS
Combinations of idelalisib with rituximab and/or bendamustine in patients with recurrent indolent non-Hodgkin lymphoma
Clinical Trials & Observations
Sven de Vos,Nina D. Wagner-Johnston,Steven E. Coutre,Ian W. Flinn,Marshall T. Schreeder,Nathan H. Fowler,Jeff P. Sharman,Ralph V. Boccia,Jacqueline C. Barrientos,Kanti R. Rai,Thomas E. Boyd,Richard R. Furman,Yeonhee Kim,Wayne R. Godfrey,John P. Leonard
LYMPHOID NEOPLASIA
THROMBOSIS AND HEMOSTASIS
TRANSPLANTATION
Zoster prophylaxis after allogeneic hematopoietic cell transplantation using acyclovir/valacyclovir followed by vaccination
Kareem Jamani,Judy MacDonald,Martin Lavoie,Tyler S. Williamson,Christopher B. Brown,Ahsan Chaudhry,Victor H. Jimenez-Zepeda,Peter Duggan,Jason Tay,Douglas Stewart,Andrew Daly,Jan Storek
-
Cover Image
Cover Image
COVER FIGURE
Fluorescence in situ hybridization image of B-cell acute lymphoblastic leukemia nuclei, using the MetaSystems BCR-ABL1 dual fusion probe, showing an atypical abnormal pattern. The signal pattern shows 2 copies of ABL1, 1 copy of BCR, and 1 fusion signal, consistent with BCR-ABL1 gene rearrangement. The patient also had an ETV6 gene rearrangement in the same nuclei. See the article by Dun et al. - PDF Icon PDF LinkFront Matter
- PDF Icon PDF LinkEditorial Board
Advertisement intended for health care professionals
Advertisement intended for health care professionals